snance

The following references may be of interest:
Leger RM, Garratty G. Weakening or loss of antibody reactivity after prewarm technique. Transfusion. 2003 Nov;43(11):1611-4. doi: 10.1046/j.1537-2995.2003.00563.x. PMID: 14617322
From the abstract of the above publication:
 
"Results: PW PBS-IAT and PW LISS-IAT showed that 40 and 47 percent of antibodies were weakened, respectively, compared to LISS-IAT; reactivity for 14 percent of antibodies was completely lost by each PW method. By PW PBS-IAT, 34 percent of antibodies were weakened compared to PBS-IAT. PW PEG-IAT showed weakened reactivity by 56 percent of antibodies compared to PEG-IAT; reactivity of seven out of seven PEG-dependent antibodies was completely lost. Of 67 antibodies, 19 percent were defined as low affinity. Of 64 samples tested by the PW method and for low-affinity antibodies, only 6 of 30 that showed decreased reactivity by the PW method appeared to be due to low-affinity antibodies; only 6 of 12 samples that appeared to contain low-affinity antibodies also showed decreased reactivity by the PW method.
Conclusion: Antibody reactivity of potentially clinically significant antibodies can be decreased or missed by PW methods. Antibody enhancement media does not ensure antibody detection by PW methods."
Other publications of possible interest:
Storry JR, Mallory D. Misidentification of anti-Vel due to inappropriate use of prewarming and adsorption techniques. Immunohematology. 1994;10(3):83-6. PMID: 15945800.
Hopkins C, Walters TK. Thermal amplitude test. Immunohematology. 2013;29(2):49-50. PMID: 24094235.
Dupuis S. Use of the prewarm method for detecting clinically significant alloantibodies in the presence of cold autoantibodies. Immunohematology. 2018 Dec;34(4):148-150. PMID: 30624948.

A few references you might find of interest:
Management of Blood Donors and Blood Donations From Individuals Found to Have a Positive Direct Antiglobulin Test. Transfusion Medicine Reviews 2012. Volume 26, Issue 2,  Pages 142-152,
Garratty G. The significance of IgG on red cell surface. Transfus Med Rev. 1987;1:47–57.
Petz LD, Garratty G. Immune Haemolytic Anaemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.

A few references you might find of interest:
Management of Blood Donors and Blood Donations From Individuals Found to Have a Positive Direct Antiglobulin Test. Transfusion Medicine Reviews 2012. Volume 26, Issue 2,  Pages 142-152,
Garratty G. The significance of IgG on red cell surface. Transfus Med Rev. 1987;1:47–57.
Petz LD, Garratty G. Immune Haemolytic Anaemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.

A few references you might find of interest:
Management of Blood Donors and Blood Donations From Individuals Found to Have a Positive Direct Antiglobulin Test. Transfusion Medicine Reviews 2012. Volume 26, Issue 2,  Pages 142-152,
Garratty G. The significance of IgG on red cell surface. Transfus Med Rev. 1987;1:47–57.
Petz LD, Garratty G. Immune Haemolytic Anaemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.

A few references you might find of interest:
Management of Blood Donors and Blood Donations From Individuals Found to Have a Positive Direct Antiglobulin Test. Transfusion Medicine Reviews 2012. Volume 26, Issue 2,  Pages 142-152,
Garratty G. The significance of IgG on red cell surface. Transfus Med Rev. 1987;1:47–57.
Petz LD, Garratty G. Immune Haemolytic Anaemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.

A few references you might find of interest:
Management of Blood Donors and Blood Donations From Individuals Found to Have a Positive Direct Antiglobulin Test. Transfusion Medicine Reviews 2012. Volume 26, Issue 2,  Pages 142-152,
Garratty G. The significance of IgG on red cell surface. Transfus Med Rev. 1987;1:47–57.
Petz LD, Garratty G. Immune Haemolytic Anaemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.

In my interactions, Patricia was a grand lady. So very kind to new talent and so gracious with her peers. I have some of the letters that she and Dr. Polly Crawford exchanged over the years regarding interesting cases and personal life happenings. They had a unique friendship! And, I have a talk at AABB in Nashville where I used a quote from her 1962 publication (!!) regarding anti-D in D+ patients with a negative DAT as missing a part of the D antigen, what we now identify with molecular methods as partial RHD. How absolutely thrilling that must have been to see new techniques prove and go further with historic theories. An excellent scientist, she is missed. Sandy Nance

In my interactions, Patricia was a grand lady. So very kind to new talent and so gracious with her peers. I have some of the letters that she and Dr. Polly Crawford exchanged over the years regarding interesting cases and personal life happenings. They had a unique friendship! And, I have a talk at AABB in Nashville where I used a quote from her 1962 publication (!!) regarding anti-D in D+ patients with a negative DAT as missing a part of the D antigen, what we now identify with molecular methods as partial RHD. How absolutely thrilling that must have been to see new techniques prove and go further with historic theories. An excellent scientist, she is missed. Sandy Nance

In my interactions, Patricia was a grand lady. So very kind to new talent and so gracious with her peers. I have some of the letters that she and Dr. Polly Crawford exchanged over the years regarding interesting cases and personal life happenings. They had a unique friendship! And, I have a talk at AABB in Nashville where I used a quote from her 1962 publication (!!) regarding anti-D in D+ patients with a negative DAT as missing a part of the D antigen, what we now identify with molecular methods as partial RHD. How absolutely thrilling that must have been to see new techniques prove and go further with historic theories. An excellent scientist, she is missed. Sandy Nance

Some references related to the Platelet Glycoprotein, GPIV
B. R. Curtis, J. G. McFarland. Human platelet antigens – 2013. Vox Sang 2013;106:93-102
Curtis BR, Ali S, Glazier AM, et al.: Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002; 42: 1173–1179
Ikeda H, Mitani T, Ohnuma M, et al.: A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989; 57: 213–217
Curtis B, McFarland J: Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematol 2009; 25: 125–135

Some references related to the Platelet Glycoprotein, GPIV
B. R. Curtis, J. G. McFarland. Human platelet antigens – 2013. Vox Sang 2013;106:93-102
Curtis BR, Ali S, Glazier AM, et al.: Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002; 42: 1173–1179
Ikeda H, Mitani T, Ohnuma M, et al.: A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989; 57: 213–217
Curtis B, McFarland J: Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematol 2009; 25: 125–135

Some references related to the Platelet Glycoprotein, GPIV
B. R. Curtis, J. G. McFarland. Human platelet antigens – 2013. Vox Sang 2013;106:93-102
Curtis BR, Ali S, Glazier AM, et al.: Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002; 42: 1173–1179
Ikeda H, Mitani T, Ohnuma M, et al.: A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989; 57: 213–217
Curtis B, McFarland J: Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematol 2009; 25: 125–135

The Sandler reference is Sandler, et al Transfusion 2015;55:199-204. I see the Italian document recommends testing for IgA, At a routine hospital level of detection (5mg/dL) there will be some patients interpreted as IgA deficient and deferred from getting CCP by the Italian guidelines that do have detectable IgA by more sensitive testing. There is no mention of IgA testing in the WHO Interim Guidance document (Teo D et al) posted on the ISBT Website. The USA American Rare Donor Program (ARDP) uses a level of 0.05 mg/dL to define IgA deficiency for donors and patients. The ARDP has an algorithm for requests for IgA deficient products, and in general,  fills requests for IgA deficient plasma containing products only for patients having anti-IgA and/or a documented anaphylactic reaction. Red cells can, in general, be washed or be frozen/deglyced for exquisitely sensitive patients.

The Sandler reference is Sandler, et al Transfusion 2015;55:199-204. I see the Italian document recommends testing for IgA, At a routine hospital level of detection (5mg/dL) there will be some patients interpreted as IgA deficient and deferred from getting CCP by the Italian guidelines that do have detectable IgA by more sensitive testing. There is no mention of IgA testing in the WHO Interim Guidance document (Teo D et al) posted on the ISBT Website. The USA American Rare Donor Program (ARDP) uses a level of 0.05 mg/dL to define IgA deficiency for donors and patients. The ARDP has an algorithm for requests for IgA deficient products, and in general,  fills requests for IgA deficient plasma containing products only for patients having anti-IgA and/or a documented anaphylactic reaction. Red cells can, in general, be washed or be frozen/deglyced for exquisitely sensitive patients.

The Sandler reference is Sandler, et al Transfusion 2015;55:199-204. I see the Italian document recommends testing for IgA, At a routine hospital level of detection (5mg/dL) there will be some patients interpreted as IgA deficient and deferred from getting CCP by the Italian guidelines that do have detectable IgA by more sensitive testing. There is no mention of IgA testing in the WHO Interim Guidance document (Teo D et al) posted on the ISBT Website. The USA American Rare Donor Program (ARDP) uses a level of 0.05 mg/dL to define IgA deficiency for donors and patients. The ARDP has an algorithm for requests for IgA deficient products, and in general,  fills requests for IgA deficient plasma containing products only for patients having anti-IgA and/or a documented anaphylactic reaction. Red cells can, in general, be washed or be frozen/deglyced for exquisitely sensitive patients.

Has the presence of anti-Sda and anti-Lub been ruled out? Both have been reported to show mixed field reactivity and both can be reactive at room temperature. Microscopic exam of reactivity in any phase would help rule out anti-Sda, and since your said it did not look like rouleaux, can it be assumed that it also did not look like an anti-Sda? That leaves possible anti-Lub.  The RBCs could be cleared of IgG and typed or an Lu(b-) RBC could be tested with serum and eluate. And, this could be an autoantibody...And then going back to a sample to blood bank for broken wrist, perhaps more going on diagnostically here, What was admission Hgb? Transfusion history is important for auto vs allo specificity. With the eluate stronger than the serum and with mf in DAT, should be concerned about possible transfused cells and this being an alloantibody.

Has the presence of anti-Sda and anti-Lub been ruled out? Both have been reported to show mixed field reactivity and both can be reactive at room temperature. Microscopic exam of reactivity in any phase would help rule out anti-Sda, and since your said it did not look like rouleaux, can it be assumed that it also did not look like an anti-Sda? That leaves possible anti-Lub.  The RBCs could be cleared of IgG and typed or an Lu(b-) RBC could be tested with serum and eluate. And, this could be an autoantibody...And then going back to a sample to blood bank for broken wrist, perhaps more going on diagnostically here, What was admission Hgb? Transfusion history is important for auto vs allo specificity. With the eluate stronger than the serum and with mf in DAT, should be concerned about possible transfused cells and this being an alloantibody.

Has the presence of anti-Sda and anti-Lub been ruled out? Both have been reported to show mixed field reactivity and both can be reactive at room temperature. Microscopic exam of reactivity in any phase would help rule out anti-Sda, and since your said it did not look like rouleaux, can it be assumed that it also did not look like an anti-Sda? That leaves possible anti-Lub.  The RBCs could be cleared of IgG and typed or an Lu(b-) RBC could be tested with serum and eluate. And, this could be an autoantibody...And then going back to a sample to blood bank for broken wrist, perhaps more going on diagnostically here, What was admission Hgb? Transfusion history is important for auto vs allo specificity. With the eluate stronger than the serum and with mf in DAT, should be concerned about possible transfused cells and this being an alloantibody.

Has the presence of anti-Sda and anti-Lub been ruled out? Both have been reported to show mixed field reactivity and both can be reactive at room temperature. Microscopic exam of reactivity in any phase would help rule out anti-Sda, and since your said it did not look like rouleaux, can it be assumed that it also did not look like an anti-Sda? That leaves possible anti-Lub.  The RBCs could be cleared of IgG and typed or an Lu(b-) RBC could be tested with serum and eluate. And, this could be an autoantibody...And then going back to a sample to blood bank for broken wrist, perhaps more going on diagnostically here, What was admission Hgb? Transfusion history is important for auto vs allo specificity. With the eluate stronger than the serum and with mf in DAT, should be concerned about possible transfused cells and this being an alloantibody.

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program

I offer the following based on experience with the MMA and antibodies to antigens of high prevalence and should not be taken as clinical recommendations.
The National Reference Laboratory for Blood Group Serology for the American Red Cross has performed Monocyte Monolayer Assays (MMAs) in over 200 cases of patients with anti-Yta in order to determine which patients have antibodies of potential clinical significance. The MMA has been performed for more than 30 years. The reason to perform the MMA is to conserve the supply of Yt(a-) units for patients who have had either had decreased survival of transfused RBCs or who have a positive MMA. But the MMA is only useful for determination of transfusion recommendations for the mother, the MMA for prediction of Hemolytic Disease of the Fetus and Newborn has not been found to be useful in studies performed in George Garratty's Research Laboratory in Los Angeles.
For cases like these, an MMA is recommended if blood is thought to be needed for the mother at delivery. Then if a physician determines that the mother can donate autologous units that would be useful. In some cases, 3 different donations can be made with the first two being frozen, one into two aliquots for possible use by the infant and one as a whole unit for the mother's possible use. The final unit can be drawn in order that it will be in-date at the time of the planned delivery. Autologous units do not generally have to follow the same rules as allogeneic donation, and can allow for more frequent donation and at a lower hemoglobin in accordance with the physician order. Alternatively or in addition, a request can be placed by an American Rare Donor Program member for potential units for delivery if autologous units cannot be obtained. And, after delivery, when the woman is eligible for donation, she should be encouraged to donate, not only for herself, but for others. Her siblings should also be tested as they have a 1:4 chance of being Yt(a-).
It is assumed that pregnancies like these are monitored by non-invasive means. Most often, antibodies such as anti-Yta, seldom clinically significant for HDFN, are monitored by titer, reviewing for increases in titer (although not mentioned), and then, by clinical protocol. Opinions vary on critical titer value in non-D antibodies, but most agree that increases in titer are reviewed for further studies or early delivery.
Perhaps not especially needed in this case, but in cases of antibodies to high prevalence antigens, knowledge of the father's ABO and D status, especially prediction of zygosity of the father's D type might be useful in the very rare event of HDFN because O D negative Yt(a-) blood may be challenging.
Sandra Nance, MS, MT(ASCP)SBB, Senior Director, American Rare Donor Program